Skip to main content

Guiheen Lawrence P.'s Form 4 filing

Adma Biologics, Inc.ADMA · filed May 23, 2025

Accession no.
0001140361-25-020376
Filed
May 23, 2025
Trade date
May 21-22, 2025
Filing delay
2 days
Rule 10b5-1 plan
Not checked

This filing lists 4 non-derivative transactions and 2 derivative transactions. Open-market sales total $182.6K. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Guiheen Lawrence P.CIK 0001554353Director

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
May 21, 2025Common StockMOption exerciseAcquired+7,779$5.96+$46,362.84122,609Direct
May 21, 2025Common StockSSaleDisposed−7,779$20.32F1−$158,069.28114,830Direct
May 22, 2025Common StockMOption exerciseAcquired+1,221$5.96+$7,277.16116,051Direct
May 22, 2025Common StockSSaleDisposed−1,221$20.12−$24,566.52114,830Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
May 21, 2025Common StockMOption exerciseDisposed−7,779$0.00$01,221Direct
May 22, 2025Common StockMOption exerciseDisposed−1,221$0.00$00Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.20 to $20.73. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)